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Objective: Migraine is linked with an elevation in vascular risk factors, ischemic stroke, and a variety of constitutional brain lesions. However, the pathogenesis 
of this relationship is still inexplicit. The link between cardiac diseases and comorbid migraine-ischemic stroke might be a vascular disease involving both heart 
and brain. In this study, an association between mitral valve prolapse (MVP), migraine, and the presence of brain white matter hyperintensities (WMHs) were 
evaluated among adult subjects with migraine headache devoid of any traditional vascular risk factors.
Materials and Methods: Four hundred subjects (200 subjects with migraine headache, 200 healthy controls; age range 18-50 years) were incorporated in the 
retrospective study. Existence of a headache compatible with migraine was diagnosed according to the International Headache Society-2 criteria. The participants 
were devoid of any known comorbid diseases, vascular risk factors or inflammatory diseases. All patients, both those with migraine and controls were screened with 
echocardiography to assess for MVP and with brain magnetic resonance imaging to evaluate the presence of any WMHs.
Results: The prevalence of MVP was found to be higher in the migraine group (p<0.011). The odds ratio (OR) for the presence of MVP in patients with migraine 
compared with controls was 2.44 [95% confidence interval (CI): 1.25-4.74; p=0.0086]. The OR for the presence of WMHs in patients with migraine compared 
with controls was 5.88 (95% CI: 3.42-10.10; p<0.0001). After modifying for confounding factors, multiple linear regression analyses revealed that migraine was 
independently and positively associated with MVP (p=0.044), tricuspid regurgitation (p=0.003), and WMHs (p<0.001), and mitral regurgitation and migraine 
was independently and positively connected with WMHs (p<0.005 and p<0.001, respectively). 
Conclusion: MVP is found to be independently associated with migraine when compared with controls. Therefore, we suggest that MVP might have an 
association with migraine. Nevertheless, we could not demonstrate any correlation between MVP and WMHs. Hence, we suggest that MVP might not be involved 
in the evolution of WMHs in migraine. 
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Amaç: Migren, iskemik inme ve bazı yapısal beyin lezyonları gelişimi gibi vasküler risk faktörlerinde artış ile ilişkilendirilmektedir. Bununla birlikte bu ilişkinin 
patogenezi halen netleşmemiştir. Kardiyak hastalıklar ve iskemik inme ile komorbidite gösterebilen migrenin bunlarla bağlantısı, hem kalp hem de beyni 
etkileyen vasküler bir hastalık olması şeklinde açıklanabilir. Bu çalışmada, geleneksel vasküler risk faktörleri olmayan genç-erişkin migren hastalarında mitral 
kapak prolapsusu (MVP) ile migren ve beyaz cevher hiperintensitesi (BCH) arasındaki ilişki incelendi. 
Gereç ve Yöntem: Bu retrospektif çalışmaya 400 olgu alındı (200 migren ve 200 sağlıklı kontrol; yaş aralığı 18-50 yaş). Migren tanısı Uluslararası Baş Ağrısı 
Toplumu-2 kriterlerine göre kondu. Katılımcıların bilinen vasküler risk faktörleri, enflamatuvar veya eşlikçi başka hastalıkları yoktu. Migrenli kişiler ve sağlıklı 
kontrollere transtorasik ekokardiyografi yapılarak MVP varlığı; beyin manyetik rezonans görüntüleme yapılarak BCH olup olmadığı tarandı. 
Bulgular: Migrenli kişilerde MVP prevelansı, kontrollere göre anlamlı yüksek (p<0,011) bulundu. Migrenli kişilerde MVP varlığı odds oranı (OR): 2,44 [%95 
güven aralığı (GA): 1,25-4,74; p=0,0086] saptandı. Migrenli kişiler ve kontrol grubu BCH varlığı açısından karşılaştırıldığında OR oranı 5,88 (%95 GA: 
3,42-10,10; p<0,001) bulundu. Karıştırıcı faktörlere göre uyarlandıktan sonra yapılan çoklu doğrusal regresyon analizleri migrenin, MVP (p=0,044), triküspid 
yetmezliği (p=0,03) ve BCH varlığı (p<0,001) ile bağımsız, pozitif korele olduğu; migrenin ve mitral yetmezliğin BCH açısından bağımsız, pozitif korelasyon 
gösterdiği gözlendi (p<0,05, p<0,001). 
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Introduction
Migraine is a very common neurovascular disorder caused by 
both hereditary (60%) and environmental factors (40%), affecting 
nearly 15% of the population (with a similar prevalence, 16.4% 
in Turkey) or about one billion people worldwide (1,2). It was 
reported to be the second leading cause of disability according 
to the annually performed “Global Years Lived With Disability” 
analysis in 2016 (3). Among its high prevalence and disability 
potency, migraine is also associated with an increase in vascular 
risk factors (both cardiovascular and cerebrovascular) according to 
risk prediction score for vascular diseases (4). 
However, whether migraine itself is the causative factor 
or whether the disease is a marker of another underlying cause 
ending with cardio-and cerebrovascular diseases remains unclear 
(3,5,6). The suggested “higher prevalence of vascular diseases 
encompassing both heart and brain” might be due to an augmented 
presence of vascular endothelial dysfunction or due to a boosting 
inflammatory response to neurogenic inflammation, elevated pro-
thrombotic factors or due to genetic predisposition. It might also 
be due to high consumption of anti-migraine medications. Also, 
the higher manifestation of vascular diseases among patients with 
migraine might be due to the “higher occurrence of constitutional 
heart anomalies” such as patent foramen ovale, atrial septal 
defects, pulmonary arteriovenous malformations, mitral valve 
prolapse (MVP), atrial septal aneurysm, and congenital heart 
disease (5,6,7).
MVP is the most frequently detected valvular condition 
affecting 2-3% of middle-aged individuals in the general 
population. Hence, MVP would be expected to affect 176 million 
people worldwide (8). According to some earlier studies, MVP was 
considered to be a disease with frequent and serious complications 
including stroke, atrial fibrillation, heart failure, and mitral 
regurgitation due to myxomatous degeneration, redundancy of 
the valve, and supraventricular arrhythmias (8,9,10). However, it 
was shown to be a benign entity, with a low occurrence of adverse 
events in a community-based FHS sample (11). 
A variety of brain lesions, including white matter hyper 
intensities (WMHs), and clinically silent infarct-like lesions, 
localized especially in the posterior circulation have been associated 
with migraine. Hence, a meta-analysis indicated a four-fold 
increased risk for the occurrence of these WMHs in people with 
migraine compared with controls (12). Although these WMHs can 
also be detected in apparently healthy people, they are frequently 
regarded as ischemic in origin, and are associated with vascular 
risk factors. The determining factors in the development of these 
WMHs are considered to be the lifetime spent with migraine 
headaches and the frequency of attacks (13,14). However, it is 
also suggested that conditions as routine risk factors for stroke 
may lead to tissue damage via vascular endothelial dysfunction 
or hypercoagulation or embolization, and these might then 
contribute to the evolution of these WMHs lesions (5,13,14). 
There are many developments in the era of migraine 
pathophysiology and treatment: The underlying mechanism 
in migraine headache is proposed to be “triggering of the 
trigemino-vascular system,” followed by liberation of calcitonin 
gene-related peptide” (CGRP) (15). Hence, many trials present 
strong verification that disturbance of the effects of endogenous 
CGRP is an effective commence to minimize migraine headaches. 
However, despite these developments in the pathophysiology of 
migraine, the mechanism by which it conveys an increased risk for 
the incidence of WMHs, even “silent infarct-like lesions,” is still 
unclear (16). 
We hypothesized that one of the factors responsible for the 
development of these WMHs in patients with migraine might 
be “the presence of MVP” in these patients (in case it exists as a 
comorbid condition). Therefore, we evaluated both the association 
of MVP with migraine, and the presence of WMHs in subjects 
with migraine with no traditional vascular risk factors.
Materials and Methods
Study Design and Patients
We analyzed data obtained from the records of patients admitted 
to our outpatient neurology clinic with a diagnosis of headache 
(compatible with migraine) from June 2014 till December 2016, 
retrospectively. The patients whose medical records contained 
both brain magnetic resonance imaging (MRI) and transthoracic 
echocardiography (ECHO) were included in the study. 
Included patients with migraine headache were those with 
duration of symptoms of ≥1 year, repetition of headache ≥2 attacks/
month, and absence of vascular risk factors along with absences of 
inflammatory or chronic illnesses such as renal, metabolic, infectious, 
or immune diseases. Patients with headache duration lasting <1 
year; those who used analgesics daily or migraine prophylaxis as 
propranolol, topiramate, or valproic acid; patients with a history 
of antecedent cerebrovascular or cardiovascular disease, arterial 
hypertension (blood pressure >130/80 mmHg), diabetes mellitus, 
or hyperlipidemia; and those who were pregnant, breast feeding, 
or on hormonal contraceptives were excluded. Patients using drugs 
inclusive of antiplatelet agents, anticoagulants, statins, or hormonal 
drugs were also excluded. Patients who might have possible 
“symptomatic migraine headache” in whom MRI demonstrated 
ischemic infarcts, brain tumors, or other conditions that may be 
affiliated with migraine headache were excluded. Patients with 
any constitutional heart disease including patent foramen ovale, 
atrial septal defect, valvular heart disease other than MVP were 
also excluded. According to these inclusion and exclusion criteria, 
200 consecutive patients diagnosed with migraine headache (143 
women (71.5%), 57 men (28.5%); mean age 33.8±7.6 (range: 18-
Sonuç: MVP varlığı, kontrollerle karşılaştırıldığında migren ile bağımsız ilişkili bulundu. Bu nedenle MVP varlığının, migren ile ilişkili olabileceği düşünüldü. 
Bununla birlikte, MVP ile BCH arasında pozitif bir korelasyon bulunamadığı için MVP’nin, migrenli olgularda BCH gelişimine bir katkısı olmadığı düşünüldü. 
Anahtar Kelimeler: Baş ağrısı, vasküler risk, kardiyovasküler risk, manyetik rezonans görüntüleme, ekokardiyografi 
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50) years] were recruited as the study group. For the control group, 
200 healthy subjects [131 women (65.5%), 69 men (34.5%); 
mean age 33.7±8.2 (range: 18-50) years] were convened from the 
hospital and laboratory staff, patients’ relatives, and the general 
population. Inclusion criteria for the control subjects were absence 
of headaches such as migraine, tension-type or cluster headaches; 
absence of any neurologic or systemic diseases; and matching 
the patients with migraine in age. The exclusion criteria for the 
control subjects were the same as for the migraine study group.
Diagnoses of migraine headache were made as stated by the 
criteria of the International Classification of Headache Disorders-2 
(17). Attack histories compatible with migraine were obtained 
in detail, subsuming disease duration (years), age at onset, 
repetition of attacks per month, average duration of headache (in 
hours), activating factors, accompanying manifestations including 
aura, site and seriousness of pain. The intensity of headache was 
appraised using a visual analogue scale (VAS) [range, 1 (minimum 
pain) to 10 (maximum pain)]. Patients were also requested to 
report the average VAS score. All patients and control subjects 
were examined thoroughly. 
This study was evaluated by the Baskent University 
Institutional Review Board and due to its retrospective design it 
was exempted from the requirement for signed informed consent; 
however, oral informed consent was still taken from all patients.
MRI
Cerebral MRI (1.5 Tesla MR 355 Inspire; General Electric, SC, 
USA) with the orbito-meatal line as a reference were performed for 
all 400 participants. The scans comprised at least three sequences: 
sagittal T1-weighted, axial T2-weighted, and axial FLAIR images 
without intravenous contrast. The slice thickness was 5 mm with a 
gap of 1 mm. A radiologist who was blinded to the clinical details 
reviewed and scored all MRI scans. 
The scans were evaluated for the existence and characteristics 
of WMHs, including apparition (focal or confluent), amount, 
measurements, dissemination (infra or supratentorial), and 
anatomic position. FLAIR images were used for the determination 
of the number and size of WMHs; focal punctate hyperintensities 
<10 mm were included, and large confluent hyperintensities 
(>9 mm) were excluded. No WMHs were detected in the corpus 
callosum. Periventricular WMHs were defined as those touching 
the ventricular system; juxtacortical WMHs were defined as 
those touching the cortical structures; all others were considered 
subcortical (18).
The subjects whom brain MRI revealed WMHs, were evaluated 
with laboratory tests for vasculitis (anticardiolipin antibodies, 
antinuclear antibody, lupus anticoagulant, anti-double-stranded 
DNA autoantibody, and C3 and C4 levels).
Echocardiographic Methods
All subjects underwent standard transthoracic ECHO (TTE) 
in accordance with the guidelines of the American Society of 
ECHO, which was performed by an experienced cardiologist who 
was blinded to any previous MVP diagnosis and clinical history 
(19). TTE was performed using a GE Health-Care Ultrasound 
Cardiology device containing a 3.5-MHz transducer. A diagnosis 
of MVP was made in case during systole, the view of parasternal 
long-axis displayed any superior displacement of mitral leaflets 
(one or more) exceeded 2 mm beyond a line attaching the annular 
hinge points to the left atrium (20). At the same time, TTE was 
also used to rule out the existence of any valvular heart diseases 
other than MVP, atrial septal defects, patent foramen ovale, systolic 
dysfunction, or other constitutional heart diseases.
Statistical Analyses
We performed the statistical analyses with IBM SPSS for 
Windows version 22.0. The Shapiro-Wilk test was used for the 
evaluation of the normality of continuous variables. The Mann-
Whitney U test was used for the assessment of differences between 
two groups, the independent samples t-test was used for continuous 
variables, and Pearson’s chi-square or Fisher’s exact test were used 
for categorical variables. Factors affecting migraine, MVP, and 
WMHs were identified using multiple logistic regression analyses. 
Significance was considered if a p value was less than 0.05. For the 
presentation of continuous variables, mean ± standard deviation 
or median (range) were used. Categorical variables are reported as 
frequencies and percentages.
Results
The characteristics of the patients with migraine headache 
and characteristics of the control groups are depicted in Table 
1. The odds ratio (OR) of MVP in patients with migraine 
headache was 2.44 [95% confidence interval (CI): 1.25-4.74; 
p=0.086], and the OR of WMHs in association with migraine 
was 5.88 (95% CI: 3.42-10.10; p<0.001). There was statistically 
significant difference between the sex of subjects with migraine 
because the number of female subjects was higher than for male 
subjects. Another statistically significant difference was found in 
the duration of migraine attacks with aura; the duration of attacks 
was longer than the duration of attacks without aura (Table 2). 
Except for these, there was no statistically significant differences 
between the characteristics of migraine headache, findings in 
ECHO or in the presence and localization of WMHs in migraine 
with and without aura group (Table 2). 
After modifying for confounding factors, linear regression 
analyses disclosed that migraine headaches were independently and 
positively connected with MVP (p=0.044), tricuspid regurgitation 
(p=0.003), and WMH (p<0.001) (Table 3). 
According to univariate analyses, MVP and mitral regurgitation 
were found to be significantly correlated (r=0.482, p<0.001). After 
regulating for confounding factors, multivariate logistic regression 
analyses revealed that mitral regurgitation was independently and 
positively correlated with MVP (Table 3). However, MVP was 
not significantly correlated with migraine characteristics or the 
presence or number of WMH (Table 3).
After altering for confounding factors, multivariate logistic 
regression analyses showed that WMH were independently and 
positively associated with female sex, age, migraine headaches, 
mitral regurgitation, and smoking compared with the normal 
brain MRI group (Table 3).
When the participants were subdivided into groups with and 
without WMH (Table 4), the presence of WMH was found to 
be significantly associated with older age, female sex, smoking, 
mitral regurgitation, tricuspid regurgitation, duration of migraine 
headache, and the frequency of migraine attacks (Table 4). 
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Table 1. Characteristics of the study participants with 
migraine and controls*
Control 
(n=200)
Migraine 
(n=200) p
Age (years) 33.7±8.2 33.8±7.6 NS
Sex (female/male) 131/69 (65.5%/34.5%)
143/57 
(71.5%/28.5%) NS
Ejection fraction 66.0±4.4 65.4±4.5 NS
Mitral valve 
prolapse 14 (7%) 31 (15.5%) 0.011
Mitral regurgitation 26 (13%) 44 (22%) 0.018
Tricuspid 
regurgitation 8 (4%) 31 (15.5%) <0.001
Atrial regurgitation - 8 (4%) 0.007
Presence of WMHs 
(%) 20 (10%) 79 (39.5%) <0.001
Presence of 
juxtacortical WMHs 8 (40%) 48 (60.8%) NS
Presence of 
subcortical WMHs 18 (90%) 77 (97.5%) NS
Presence of 
periventricular 
WMHs
- 16 (20.3%) -
Presence of 
infratentorial WMHs - 14 (17.7%) -
Number of WMHs 2 (1-6) 5 (1-15) <0.001
Number of 
juxtacortical WMHs 0 (0-2) 1 (0-8) 0.017
Number of 
subcortical WMHs 2 (0-5) 3 (0-13) 0.010
Number of 
periventricular 
WMHs
- 0 (0-4) 0.029
Number of 
infratentorial WMHs - 0 (0-3) 0.044
Aura - 64 (32%) -
Migraine disease 
duration (years) - 5 (1-30) -
Headache frequency 
(no/month) - 3 (2-13) -
Headache duration 
(h) - 24 (1-96) -
Visual analogue 
scale score - 8 (4-10) -
Smoking (≤pack/
day) 33 (16.5%) 41 (20.5%) NS
*Data are reported as number (%), mean ± standard deviation, or median 
(range).
WMHs: White matter hyperintensities, NS: Not significant (p>0.05)
Table 2. Characteristics of the migraine participants with 
and without aura*
Migraine 
without aura 
(n=136)
Migraine 
with aura 
(n=64)
p
Age (years) 35.7±7.1 33.9±8.2 NS
Sex (female/male) 89/47 
(65.5%/34.5%)
54/10 
(84.3%/15.6%)
0.007
Ejection fraction 65.2±4.3 66±4.3 NS
Mitral valve 
prolapse
18 (13%) 13 (20%) NS
Mitral regurgitation 29 (21.3%) 15 (23.4%) NS
Tricuspid 
regurgitation
23 (16.9%) 8 (12.5%) NS
Atrial regurgitation 6 (4.41%) 2 (3.1%) NS
Presence of WMHs 
(%)
51 (37.5%) 29 (45.3%) NS
Presence of 
juxtacortical WMHs
32 (62.7%) 16 (55.2%) NS
Presence of 
subcortical WMHs
50 (98%) 27 (93.1%) NS
Presence of 
periventricular 
WMHs
13 (25.5%) 3 (10.3%) NS
Presence of 
infratentorial WMHs
7 (13.7%) 7 (24.1%) NS
Number of WMHs 51 (1-6) 28 (1-5) NS
Number of 
juxtacortical WMHs
31 (1-11) 16 (2-6) NS
Number of 
subcortical WMHs
50 (1-13) 26 (1-7) NS
Number of 
periventricular 
WMHs
13 (3-6) 3 (0-1) NS
Number of 
infratentorial WMHs
7 (1-4) 7 (1-6) NS
Migraine disease 
duration (years)
6 (1-30) 10 (1-30) NS
Headache 
frequency  
(no/month)
5 (2-137 4 (2-13) NS
Headache duration 
(h)
19 (1-96) 30 (4-96) 0.001
Visual analogue 
scale score
7 (4-9) 8 (6-10) NS
Smoking (≤pack/
day)
27 (19.8%) 14 (21.8%) NS
*Data are reported as number (%), mean ± standard deviation, or median 
(range).
WMHs: White matter hyperintensities, NS: Not significant (p>0.05)
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Discussion
A high prevalence of MVP and migraine comorbidity (as 20-
59%) has been shown (21). Many brain MRI studies reported a 
relatively high prevalence of subclinical WMH in patients with 
migraine headache (13,14,22). Regarding these data, we wanted 
to evaluate the relation between MVP and migraine in conjunction 
with WMHs. 
Our study also demonstrated that a higher number of 
patients with migraine headache encountered MVP and mild 
valve regurgitation compared with the control group (p=0.044). 
There was no statistically significant difference between MVP and 
migraine attacks with or without aura (Table 1, 2). The risk for 
MVP was 2.4-fold higher in patients with migraine than controls 
(OR: 2.44; 95% CI: 1.25-4.74; p=0.0086) (Table 3). Although 
mild mitral regurgitation was found to be independently associated 
with WMH, no association could be elicited between MVP and 
the presence of WMHs (Table 3). 
Our results are in line with previous studies reporting MVP 
to be more frequent in subjects with migraine headache than 
in controls (21,23), although there are some conflicting results 
(24,25). The sample group was quite small in one study, and the 
mean age of the participants in another study was older than in our 
study, and no data were included on vascular risk factors (24,25).
In our study, the prevalence of MVP was found as 15.5% 
in subjects with migraine headaches, similar to the reported 
prevalence of MVP in the literature (15-25%) (8,23). A previous 
study reported that 27.8% patients with MVP had migraine 
headache, which was significantly higher than the expected 
number in the general population (approximately 10%) (26). 
Although several mechanisms have been suggested regarding 
the causal association between the generation of migraine headaches 
and the development of MVP, the underlying mechanism is still 
obscure. It is suggested that shortened platelet survival and 
loss of endothelial continuity could initiate platelet activation 
and aggregation (21,23). As such, migraine headaches could be 
generated following the release of serotonin from these aggregated 
platelets (7,23). Paroxysmal arrhythmias that may accompany 
MVP syndrome may also increase the likelihood of embolization, 
leading to the formation of silent infarct-like lesions or WMHs 
(27).
Migraine headache is reported to be a risk factor for development 
of WMHs and the prevalence of WMHs in patients with migraine 
ranges from 14% to 59% (13,28,29). One suggested mechanisms 
for this is “oligemia triggered by repeated and prolonged periods 
of migraine attacks affecting the vulnerable small deep penetrating 
arteries” (13,28). In the present study, WMHs were detected 5.88 
times more frequently in patients with migraine headaches than in 
controls, and we also showed that the presence of WMHs increased 
according to the (increased) headache frequency and duration, 
concordant with previous studies (Table 4). The association 
between WMHs and both the duration and frequency of migraine 
attacks suggest that the “migraine attack” itself plays a role in the 
pathophysiology. 
Mitral regurgitation and other co-factors (such as age, 
female sex, mitral regurgitation, and smoking) are found to be 
independent factors associated with WMH (Table 3). Hence, these 
co-factors may also contribute to the pathophysiology of WMH. 
Table 3. Factors affecting migraine, mitral valve prolapse, 
and white matter hyperintensities*
Odds 
ratio
95% 
confidence 
interval
p
Migraine
Mitral valve 
prolapse
2.079 1.021-4.234 0.044
Tricuspid 
regurgitation
3.583 1.542-8.327 0.003
White matter 
hyperintensities
5.499 3.171-9.534 <0.001
White matter 
hyperintensities
Sex (female) 2.412 1.301-4.473 0.005
Mitral 
regurgitation
2.395 1.306-4.391 0.005
Migraine 5.740 3.265-10.090 <0.001
Age 1.052 1.018-1.088 0.003
Smoking 2.158 1.146-4.065 0.017
*Data are reported as the odds ratio and 95% confidence interval
Table 4. Characteristics according to the presence of white 
matter hyperintensities on magnetic resonance imaging*
WMHs 
absent 
(n=301)
WMHs 
present 
(n=99)
p
Age (years) 33.1±7.9 35.6±7.7 0.006
Ejection fraction 65.7±4.5 65.8±4.3 NS
Sex (female/male) 107/194 
(35.5%/64.5%)
19/80 
(19.2%/80.8%)
0.004
Smoking (≤pack/
day)
49 (16.3%) 25 (25.3%) 0.046
Mitral regurgitation 40 (13.3%) 30 (30.3%) <0.001
Tricuspid 
regurgitation
23 (7.6%) 16 (16.2%) 0.022
Atrial regurgitation 4 (1.3%) 4 (4%) NS
Mitral valve 
prolapse
30 (10%) 15 (15.2%) NS
Aura 36 (29.8%) 28 (35.4%) NS
Migraine disease 
duration (years)
4 (1-30) 10 (1-30) 0.024
Headache 
frequency (no/
month)
3 (2-13) 4 (2-13) 0.011
Headache duration 
(hours)
24 (1-96) 24 (4-96) NS
Visual analogue 
scale score
7 (5-10) 8 (4-10) NS
*Data are reported as number (%), mean ± standard deviation, or median 
(range).
MRI: Magnetic resonance imaging, WMHs: White matter hyperintensities, NS: 
Not significant (p>0.05)
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Therefore, the relationship between mitral regurgitation and 
WMH still merits further investigation. 
In this study, the anatomic location of WMHs differed 
between the groups. In subjects with migraine headache, WMHs 
were mostly located in the subcortical region, less juxtacortically; 
and only subjects with migraine headache had WMHs located 
in the periventricular and infratentorial regions (Table 1). These 
findings are in line with previous studies (13,28,29). However, 
in contrast to our findings, in another study no differences in the 
location of deep and periventricular WMHs could be elicited 
between migraineurs and controls (14). Accordingly, there may be 
different mechanisms affecting the development of these lesions in 
association with migraine. Hence, some previous studies included 
participants older in age with higher vascular risk factors (14). 
There are also studies reporting no increased number of WMHs 
in association with migraine compared with controls (30,31), 
but those studies had either smaller sample numbers than ours 
or included no information about the vascular risk factors of their 
participants (30,31).
MVP is a common decadence cardiac valvulopathy of unknown 
etiology inclining to mitral regurgitation, heart failure, and even 
sudden fatality. Subjects with MVP have a greater chance to 
experience mitral regurgitation than those without, even if the 
valvular regurgitation is trace or mild (11,32). The prevalence 
of mild mitral regurgitation was 68.9% in our study, consistent 
with previous reports (11). The most common complication 
of MVP is worsening of the mitral regurgitation. It causes 
diastolic dysfunction of the left atrium and left ventricle, cardiac 
arrhythmias, and subsequent heart failure, with an increased risk 
for infective endocarditis. Hence, 2.4% of patients with MVP 
experience thromboembolic events (33). 
As far as we know, our study is the first to display a connection 
between MVP and WMHs in migraine. The unique feature of our 
study design was the simultaneous assessment of an association 
between MVP and WMH in migraine. In order to minimize the 
effects of age-dependent WMHs, we included patients aged <50 
years who were devoid of any vascular risk factors or inflammatory 
diseases.
Study Limitations
There are many limitations of our study, such as its retrospective 
design and lack of trans-esophageal ECHO examination, because 
it is a better tool for diagnosing MVP. Furthermore, we could 
not strictly exclude risk factors such as smoking and obesity; we 
excluded heavy smokers (>1 pack/day), but did not exclude all 
cigarette smokers. However, there were no significant differences in 
smoking habits between the subjects with migraine and controls. 
We did not calculate the body mass indexes of the participants, 
which might also give more information. The association between 
migraine, WMHs, and MVP might have been evaluated further 
if we could have studied markers of thrombosis and coagulation 
factors in detail. 
Conclusion
We found that MVP was independently associated with 
migraine headache, but we found no correlation between MVP 
and WMHs. We suggest that MVP is not causally involved in 
the development of WMHs associated with migraine headache. 
Further prospective studies should evaluate the relationships 
between migraine, WMHs, and MVP.
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